Marble Harbor Investment Counsel LLC Sells 455 Shares of Johnson & Johnson (NYSE:JNJ)

Marble Harbor Investment Counsel LLC decreased its position in Johnson & Johnson (NYSE:JNJ) by 0.8% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 55,664 shares of the company’s stock after selling 455 shares during the period. Johnson & Johnson comprises 1.4% of Marble Harbor Investment Counsel LLC’s portfolio, making the stock its 23rd biggest position. Marble Harbor Investment Counsel LLC’s holdings in Johnson & Johnson were worth $8,287,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in JNJ. Nordea Investment Management AB raised its stake in shares of Johnson & Johnson by 88.0% during the 2nd quarter. Nordea Investment Management AB now owns 17,222,162 shares of the company’s stock worth $2,382,514,000 after purchasing an additional 8,062,204 shares in the last quarter. BlackRock Inc. raised its stake in shares of Johnson & Johnson by 0.6% during the 2nd quarter. BlackRock Inc. now owns 193,714,044 shares of the company’s stock worth $27,242,005,000 after purchasing an additional 1,168,129 shares in the last quarter. California Public Employees Retirement System raised its stake in shares of Johnson & Johnson by 8.9% during the 3rd quarter. California Public Employees Retirement System now owns 10,616,780 shares of the company’s stock worth $1,580,626,000 after purchasing an additional 864,547 shares in the last quarter. MUFG Securities EMEA plc raised its stake in shares of Johnson & Johnson by 124.7% during the 2nd quarter. MUFG Securities EMEA plc now owns 1,506,456 shares of the company’s stock worth $211,853,000 after purchasing an additional 836,139 shares in the last quarter. Finally, Handelsbanken Fonder AB raised its stake in shares of Johnson & Johnson by 290.9% during the 2nd quarter. Handelsbanken Fonder AB now owns 1,114,004 shares of the company’s stock worth $156,662,000 after purchasing an additional 829,053 shares in the last quarter. Hedge funds and other institutional investors own 67.44% of the company’s stock.

A number of equities research analysts have recently issued reports on the company. Stifel Nicolaus cut Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Wednesday, August 19th. Cantor Fitzgerald increased their price target on Johnson & Johnson from $168.00 to $180.00 and gave the company an “overweight” rating in a research note on Wednesday, October 14th. ValuEngine upgraded Johnson & Johnson from a “sell” rating to a “hold” rating in a research note on Monday, August 3rd. Raymond James restated a “buy” rating on shares of Johnson & Johnson in a research note on Friday. Finally, Credit Suisse Group increased their price target on Johnson & Johnson from $163.00 to $168.00 and gave the company an “outperform” rating in a research note on Wednesday, October 14th. One research analyst has rated the stock with a sell rating, four have given a hold rating and ten have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $164.93.

In other news, EVP Kathryn E. Wengel sold 16,115 shares of the stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $153.52, for a total transaction of $2,473,974.80. Following the sale, the executive vice president now directly owns 66,658 shares of the company’s stock, valued at approximately $10,233,336.16. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.27% of the company’s stock.

Shares of NYSE JNJ opened at $146.36 on Friday. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.48 and a quick ratio of 1.24. The stock’s fifty day moving average price is $145.51 and its two-hundred day moving average price is $146.57. Johnson & Johnson has a one year low of $109.16 and a one year high of $157.00. The firm has a market cap of $385.30 billion, a price-to-earnings ratio of 23.01, a P/E/G ratio of 3.04 and a beta of 0.69.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Sunday, October 18th. The company reported $2.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.98 by $0.22. The company had revenue of $21.08 billion for the quarter, compared to analyst estimates of $20.15 billion. Johnson & Johnson had a return on equity of 34.64% and a net margin of 21.01%. Johnson & Johnson’s quarterly revenue was up 1.7% on a year-over-year basis. During the same period in the prior year, the firm posted $2.12 EPS. On average, equities analysts anticipate that Johnson & Johnson will post 7.99 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be issued a dividend of $1.01 per share. This represents a $4.04 annualized dividend and a dividend yield of 2.76%. The ex-dividend date is Monday, November 23rd. Johnson & Johnson’s dividend payout ratio (DPR) is currently 46.54%.

Johnson & Johnson Profile

Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.

Further Reading: How is the S&P 500 index different from the DJIA?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.